Is Generation Bio Stock a Good Investment?

Generation Bio Investment Advice

  GBIO
To provide specific investment advice or recommendations on Generation Bio Co stock, we recommend investors consider the following general factors when evaluating Generation Bio Co. This will help you to make an informed decision on whether to include Generation Bio in one of your diversified portfolios:
  • Examine Generation Bio's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
  • Research Generation Bio's leadership team and their track record. Good management can help Generation Bio navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
  • Consider the overall health of the Biotechnology space and any emerging trends that could impact Generation Bio's business and its evolving consumer preferences.
  • Compare Generation Bio's performance and market position to its competitors. Analyze how Generation Bio is positioned in terms of product offerings, innovation, and market share.
  • Check if Generation Bio pays a dividend and its dividend yield and payout ratio.
  • Review what financial analysts are saying about Generation Bio's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Generation Bio Co stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Generation Bio Co is a good investment.
 
Sell
 
Buy
Cautious Hold
We provide advice to complement the regular expert consensus on Generation Bio. Our dynamic recommendation engine utilizes a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. To make sure Generation Bio Co is not overpriced, please check out all Generation Bio fundamentals, including its current ratio, market capitalization, and the relationship between the cash and equivalents and earnings per share . Please also validate Generation Bio number of shares shorted to confirm your buy or sell decision is consistent with all fundamental data available and that the company can sustain itself in the current economic cycle.

Market Performance

Very WeakDetails

Volatility

RiskyDetails

Hype Condition

Over hypedDetails

Current Valuation

UndervaluedDetails

Odds Of Distress

Very HighDetails

Economic Sensitivity

Hyperactively responds to market trendsDetails

Investor Sentiment

ImpartialDetails

Analyst Consensus

BuyDetails

Financial Strenth (F Score)

HealthyDetails

Financial Leverage

Not RatedDetails

Reporting Quality (M-Score)

Unlikely ManipulatorDetails

Examine Generation Bio Stock

Researching Generation Bio's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 15.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.88. Some equities with similar Price to Book (P/B) outperform the market in the long run. Generation Bio recorded a loss per share of 2.19. The entity had not issued any dividends in recent years.
To determine if Generation Bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Generation Bio's research are outlined below:
Generation Bio generated a negative expected return over the last 90 days
Generation Bio has high historical volatility and very poor performance
Generation Bio may become a speculative penny stock
Generation Bio has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 5.9 M. Net Loss for the year was (126.61 M) with profit before overhead, payroll, taxes, and interest of 0.
Generation Bio Co currently holds about 301.17 M in cash with (52.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.07, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Over 84.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: Generation Bio Co. Reports Q3 2024 Financials and Progress - TipRanks
Generation Bio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Generation Bio Co. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Generation Bio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
22nd of February 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View
Earnings surprises can significantly impact Generation Bio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Generation Bio's investors have experienced.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-08-07
2024-06-30-0.28-0.31-0.0310 
2024-11-07
2024-09-30-0.28-0.230.0517 
2023-11-09
2023-09-30-0.5-0.430.0714 
2023-05-10
2023-03-31-0.46-0.53-0.0715 
2024-03-06
2023-12-31-0.45-0.53-0.0817 
2021-08-11
2021-06-30-0.47-0.55-0.0817 
2022-05-05
2022-03-31-0.52-0.61-0.0917 
2022-11-03
2022-09-30-0.67-0.530.1420 

Know Generation Bio's Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Generation Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Generation Bio Co backward and forwards among themselves. Generation Bio's institutional investor refers to the entity that pools money to purchase Generation Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Geode Capital Management, Llc2024-09-30
1.1 M
State Street Corp2024-06-30
980.5 K
Ubs Group Ag2024-06-30
837.8 K
Partner Fund Management Lp2024-09-30
787.9 K
Renaissance Technologies Corp2024-09-30
594.3 K
Deutsche Bank Ag2024-06-30
558 K
D. E. Shaw & Co Lp2024-09-30
488.1 K
Dimensional Fund Advisors, Inc.2024-09-30
441.1 K
Charles Schwab Investment Management Inc2024-09-30
423.3 K
T. Rowe Price Associates, Inc.2024-06-30
9.5 M
Fmr Inc2024-09-30
5.3 M
Note, although Generation Bio's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Generation Bio's market capitalization trends

The company currently falls under 'Micro-Cap' category with a current market capitalization of 93.51 M.

Market Cap

249.52 Million

Generation Bio's profitablity analysis

Last ReportedProjected for Next Year
Return On Tangible Assets(0.34)(0.35)
Return On Capital Employed(0.41)(0.43)
Return On Assets(0.34)(0.35)
Return On Equity(0.62)(0.59)
Determining Generation Bio's profitability involves analyzing its financial statements and using various financial metrics to determine if Generation Bio is a good buy. For example, gross profit margin measures Generation Bio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Generation Bio's profitability and make more informed investment decisions.

Evaluate Generation Bio's management efficiency

Generation Bio has return on total asset (ROA) of (0.1929) % which means that it has lost $0.1929 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.865) %, meaning that it created substantial loss on money invested by shareholders. Generation Bio's management efficiency ratios could be used to measure how well Generation Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of November 2024, Return On Tangible Assets is likely to drop to -0.35. In addition to that, Return On Capital Employed is likely to drop to -0.43. At this time, Generation Bio's Non Currrent Assets Other are very stable compared to the past year. As of the 26th of November 2024, Asset Turnover is likely to grow to 0.01, while Total Assets are likely to drop about 302.1 M.
Last ReportedProjected for Next Year
Book Value Per Share 3.15  2.72 
Tangible Book Value Per Share 3.15  2.72 
Enterprise Value Over EBITDA(1.03)(1.09)
Price Book Value Ratio 0.52  0.55 
Enterprise Value Multiple(1.03)(1.09)
Price Fair Value 0.52  0.55 
Enterprise Value249.5 M237 M
The operational strategies employed by Generation Bio management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Beta
2.818

Basic technical analysis of Generation Stock

As of the 26th of November, Generation Bio retains the Market Risk Adjusted Performance of (0.23), standard deviation of 5.18, and Risk Adjusted Performance of (0.11). Generation Bio technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.

Generation Bio's insider trading activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Generation Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Generation Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Generation Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Howze Yalonda over a month ago
Disposition of 983 shares by Howze Yalonda of Generation Bio subject to Rule 16b-3
 
Phillip Samayoa over two months ago
Disposition of 1590 shares by Phillip Samayoa of Generation Bio at 1.91 subject to Rule 16b-3
 
Matthew Stanton over three months ago
Disposition of 7437 shares by Matthew Stanton of Generation Bio subject to Rule 16b-3
 
Norkunas Matthew over three months ago
Acquisition by Norkunas Matthew of 1674 shares of Generation Bio subject to Rule 16b-3
 
Howze Yalonda over three months ago
Disposition of 983 shares by Howze Yalonda of Generation Bio at 2.93 subject to Rule 16b-3
 
Matthew Stanton over three months ago
Disposition of 1674 shares by Matthew Stanton of Generation Bio subject to Rule 16b-3
 
Paone Antoinette over three months ago
Disposition of 6719 shares by Paone Antoinette of Generation Bio at 2.74 subject to Rule 16b-3
 
Mcdonough Geoff over three months ago
Acquisition by Mcdonough Geoff of 240470 shares of Generation Bio at 1. subject to Rule 16b-3
 
Appelhans Dannielle over three months ago
Acquisition by Appelhans Dannielle of 60000 shares of Generation Bio at 3.32 subject to Rule 16b-3
 
Norkunas Matthew over six months ago
Acquisition by Norkunas Matthew of 1674 shares of Generation BioCo subject to Rule 16b-3
 
Howze Yalonda over six months ago
Disposition of 30 shares by Howze Yalonda of Generation BioCo at 3.7 subject to Rule 16b-3
 
Tracy Zimmermann over six months ago
Exercise or conversion by Tracy Zimmermann of 5021 shares of Generation BioCo subject to Rule 16b-3

Generation Bio's Outstanding Corporate Bonds

Generation Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Generation Bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Generation bonds can be classified according to their maturity, which is the date when Generation Bio Co has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Understand Generation Bio's technical and predictive indicators

Using predictive indicators to make investment decisions involves analyzing Generation Bio's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.

Consider Generation Bio's intraday indicators

Generation Bio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Generation Bio stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Generation Bio time-series forecasting models is one of many Generation Bio's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Generation Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Generation Stock media impact

Far too much social signal, news, headlines, and media speculation about Generation Bio that are available to investors today. That information is available publicly through Generation media outlets and privately through word of mouth or via Generation internal channels. However, regardless of the origin, that massive amount of Generation data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Generation Bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Generation Bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Generation Bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Generation Bio alpha.

Generation Bio Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Generation Bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Generation Bio Corporate Management

Robert KotinCoFounder AdvisorProfile
Sara BestenChief OfficerProfile
Tracy ZimmermannChief OfficerProfile
Phillip SamayoaChief OfficerProfile
Jasmin TowerChief OfficerProfile
MBA MDChief OfficerProfile
Cameron MDCEO and PresidentProfile
When determining whether Generation Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Generation Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Generation Bio Co Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Generation Bio Co Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Generation Bio Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Generation Bio. If investors know Generation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Generation Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.19)
Revenue Per Share
0.28
Quarterly Revenue Growth
2.52
Return On Assets
(0.19)
Return On Equity
(0.86)
The market value of Generation Bio is measured differently than its book value, which is the value of Generation that is recorded on the company's balance sheet. Investors also form their own opinion of Generation Bio's value that differs from its market value or its book value, called intrinsic value, which is Generation Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Generation Bio's market value can be influenced by many factors that don't directly affect Generation Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Generation Bio's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Generation Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Generation Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.